Eli Lilly and Company in 3 stories
The narratives LLY currently appears in, with its side and exposure in each.
Bull side
2 stories- GLP-1 Eats Everything
LLY in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
Supply-constrained franchise with pricing power.
- China Becomes Pharma's Global R&D Engine
LLY in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Lilly can supplement its internal pipeline at attractive speed and cost through deals such as its acquisition of ex-China rights to Hengrui's investigational incretin program.
Bear side
1 story- America Imports the World's Drug Prices
LLY in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Its premium-priced, high-growth drug portfolio has substantial earnings sensitivity to lower US benchmark prices.